eprintid: 10151872 rev_number: 8 eprint_status: archive userid: 699 dir: disk0/10/15/18/72 datestamp: 2022-07-12 15:44:45 lastmod: 2024-10-25 15:47:56 status_changed: 2022-07-12 15:44:45 type: article metadata_visibility: show sword_depositor: 699 creators_name: Flynn, Michael J creators_name: Ledermann, Jonathan A title: Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer ispublished: pub subjects: UCH divisions: C10 divisions: G99 divisions: B02 divisions: UCL divisions: D19 keywords: DNA damage response, PARP inhibitors, Platinum resistance, VEGF inhibitors, immune checkpoint inhibitors note: © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. abstract: Definitions of platinum resistance have been questioned and changed over the last five years, even though no predictive biomarker of resistance exists. These have sculpted how we approach platinum retreatment and, consequently, how we devise new treatment strategies for those patients with tumour progression on platinum therapy. Platinum-non-eligible ovarian cancer is treated with single-agent non-platinum drugs. When bevacizumab can be added to chemotherapy, progression-free survival improves significantly. For patients with a BRCA mutation, PARP inhibitor monotherapy is an option compared to chemotherapy. There is currently no clearly identified role for immune-checkpoint inhibition in this patient population. This review describes some of the challenges in treating patients with platinum resistance and suggests refinements in the selection of patients most likely to benefit from targeting a DNA damage response, angiogenesis or immune modulation. It also describes novel agents of interest and possible mechanisms of the synergy of therapeutic combinations. date: 2022-05-12 date_type: published publisher: OAE Publishing Inc. official_url: https://dx.doi.org/10.20517/cdr.2022.13 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1964910 doi: 10.20517/cdr.2022.13 medium: Electronic-eCollection lyricists_name: Ledermann, Jonathan lyricists_id: JALED70 actors_name: Kalinowski, Damian actors_id: DKALI47 actors_role: owner full_text_status: public publication: Cancer Drug Resistance volume: 5 number: 2 pagerange: 424-435 event_location: United States citation: Flynn, Michael J; Ledermann, Jonathan A; (2022) Ovarian cancer recurrence: is the definition of platinum resistance modified by PARPi and other intervening treatments? The evolving landscape in the management of platinum-resistant ovarian cancer. Cancer Drug Resistance , 5 (2) pp. 424-435. 10.20517/cdr.2022.13 <https://doi.org/10.20517/cdr.2022.13>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10151872/1/Ledermann_Ovarian%20cancer%20recurrence_VoR.pdf